EUVIMEDEUVIMED entdecken
Crossref

Efficacy, Tolerability and Cost Effectiveness of Cytosponge in Patients with Barrett Esophagus. A Systemic Review and Meta Analysis

Bheesham ., Fizza Hanif, Anitha Sangem, Aderinsola Wale Oyedele, FNU Geeta, Sona Kumari, Muneeb Khalid, Hira Riaz

Fortune Journal of Health Sciences · 2026 · 09 (03)

DOI: 10.26502/fjhs.435 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Fortune Journal of Health Sciences, 2026. Verfasst von Bheesham . und 7 weiteren Autor:innen.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Barrett's esophagus (BE) is a premalignant condition associated with an increased risk of esophageal adenocarcinoma.Early detection remains challenging because conventional endoscopic screening is invasive, resourceintensive, and unsuitable for large-scale implementation.The Cytosponge-trefoil factor 3 (TFF3) test is a minimally invasive, non-endoscopic alternative designed to improve accessibility to BE detection.This meta-analysis evaluates its diagnostic accuracy and cost-effectiveness. Methods:A systematic search of PubMed and Web of Science was conducted for studies published through January 2026.Eligible studies assessed the diagnostic performance of Cytosponge-TFF3 compared with endoscopy and histology.Two reviewers independently performed study selection, data extraction, and quality assessment using QUADAS-2.A bivariate random-effects model generated pooled sensitivity, specificity, diagnostic odds ratios (DOR), and summary receiver operating characteristic (SROC) curves.

Results

Ten studies comprising 4,005 participants were included.For BE with circumferential length ≥1 cm (C1), pooled sensitivity and specificity were 0.75 (95% CI: 0.70-0.79)and 0.88 (95% CI: 0.76-0.94),Results: Ten studies comprising 4,005 participants were included.For BE with circumferential length ≥1 cm (C1), pooled sensitivity and specificity were 0.75 (95% CI: 0.70-0.79)and 0.88 (95% CI: 0.76-0.94),with an AUROC of 0.80.For BE of any circumferential length, sensitivity increased to 0.81 (95% CI: 0.76-0.85)and specificity to 0.89 (95% CI: 0.82-0.93),with an AUROC of 0.90, indicating excellent overall performance.Across economic analyses, Cytosponge-based strategies demonstrated favorable incremental cost-effectiveness ratios compared with both no screening and endoscopy, while reducing endoscopic utilization.

Conclusions

Cytosponge-TFF3 demonstrates good diagnostic accuracy for detecting BE and represents an effective and cost-efficient alternative to conventional endoscopic screening, particularly for population-based and primary care implementation.

Zitieren

APA

., B., Hanif, F., Sangem, A., Oyedele, A. W., Geeta, F., Kumari, S., Khalid, M., & Riaz, H. (2026). Efficacy, Tolerability and Cost Effectiveness of Cytosponge in Patients with Barrett Esophagus. A Systemic Review and Meta Analysis. Fortune Journal of Health Sciences, 09(03). https://doi.org/10.26502/fjhs.435

Vancouver

. B, Hanif F, Sangem A, Oyedele AW, Geeta F, Kumari S, et al. Efficacy, Tolerability and Cost Effectiveness of Cytosponge in Patients with Barrett Esophagus. A Systemic Review and Meta Analysis. Fortune Journal of Health Sciences. 2026;09(03). doi:10.26502/fjhs.435

BibTeX
@article{2026,
  author = {., Bheesham and Hanif, Fizza and Sangem, Anitha and Oyedele, Aderinsola Wale and Geeta, FNU and Kumari, Sona and Khalid, Muneeb and Riaz, Hira},
  title = {Efficacy, Tolerability and Cost Effectiveness of Cytosponge in Patients with Barrett Esophagus. A Systemic Review and Meta Analysis},
  journal = {Fortune Journal of Health Sciences},
  year = {2026},
  volume = {09},
  number = {03},
  doi = {10.26502/fjhs.435}
}
Kostenlos starten →